# Stride, Inc.: financial statements, quarterly

LRN · NYSE · CIK 1157408 · [Other](/sectors/other.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/lrn.md) · [Financials](/companies/lrn/financials.md) · [Filings](/companies/lrn/filings.md) · [Insiders](/companies/lrn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lrn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [505](/filings/0001558370-25-000455.md) | [521](/filings/0001558370-25-005882.md) | [534 d](/filings/0001104659-26-090515.md) | [551](/filings/0001104659-25-103288.md) | [587](/filings/0001104659-26-007063.md) | [613](/filings/0001104659-26-050510.md) | [654 d](/filings/0001104659-26-090515.md) | [621](/filings/0001104659-26-117480.md) | [631](/filings/0001104659-26-007063.md) | [630](/filings/0001104659-26-050510.md) | [636 d](/filings/0001104659-26-090515.md) | [639](/filings/0001104659-26-117480.md) |
| Cost of revenue | $m | [304](/filings/0001558370-25-000455.md) | [320](/filings/0001558370-25-005882.md) | [346 d](/filings/0001104659-26-090515.md) | [335](/filings/0001104659-25-103288.md) | [347](/filings/0001104659-26-007063.md) | [364](/filings/0001104659-26-050510.md) | [415 d](/filings/0001104659-26-090515.md) | [379](/filings/0001104659-26-117480.md) | [372](/filings/0001104659-26-007063.md) | [398](/filings/0001104659-26-050510.md) | [419 d](/filings/0001104659-26-090515.md) | [398](/filings/0001104659-26-117480.md) |
| Gross profit | $m | [201](/filings/0001558370-25-000455.md) | [201](/filings/0001558370-25-005882.md) | [188 d](/filings/0001104659-26-090515.md) | [216](/filings/0001104659-25-103288.md) | [240](/filings/0001104659-26-007063.md) | [249](/filings/0001104659-26-050510.md) | [239 d](/filings/0001104659-26-090515.md) | [242](/filings/0001104659-26-117480.md) | [260](/filings/0001104659-26-007063.md) | [232](/filings/0001104659-26-050510.md) | [217 d](/filings/0001104659-26-090515.md) | [241](/filings/0001104659-26-117480.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [117](/filings/0001558370-25-000455.md) | [113](/filings/0001558370-25-005882.md) | [115 d](/filings/0001104659-26-090515.md) | [169](/filings/0001104659-25-103288.md) | [115](/filings/0001104659-26-007063.md) | [119](/filings/0001104659-26-050510.md) | [123 d](/filings/0001104659-26-090515.md) | [173](/filings/0001104659-26-117480.md) | [113](/filings/0001104659-26-007063.md) | [102](/filings/0001104659-26-050510.md) | [111 d](/filings/0001104659-26-090515.md) | [157](/filings/0001104659-26-117480.md) |
| Operating income | $m | [84.3](/filings/0001558370-25-000455.md) | [88.3](/filings/0001558370-25-005882.md) | [73.7 d](/filings/0001104659-26-090515.md) | [47.3](/filings/0001104659-25-103288.md) | [125](/filings/0001104659-26-007063.md) | [131](/filings/0001104659-26-050510.md) | [56.9 d](/filings/0001104659-26-090515.md) | [69.0](/filings/0001104659-26-117480.md) | [147](/filings/0001104659-26-007063.md) | [129](/filings/0001104659-26-050510.md) | [106 d](/filings/0001104659-26-090515.md) | [84.3](/filings/0001104659-26-117480.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [22.2](/filings/0001558370-25-000455.md) | [24.7](/filings/0001558370-25-005882.md) | [16.1 d](/filings/0001104659-26-090515.md) | [11.3](/filings/0001104659-25-103288.md) | [33.4](/filings/0001104659-26-007063.md) | [35.5](/filings/0001104659-26-050510.md) | [12.9 d](/filings/0001104659-26-090515.md) | [14.4](/filings/0001104659-26-117480.md) | [34.0](/filings/0001104659-26-007063.md) | [31.5](/filings/0001104659-26-050510.md) | [22.8 d](/filings/0001104659-26-090515.md) | [17.8](/filings/0001104659-26-117480.md) |
| Net income | $m | [66.8](/filings/0001558370-25-005882.md) | [69.7](/filings/0001558370-25-005882.md) | [62.8 d](/filings/0001104659-26-090515.md) | [40.9](/filings/0001104659-26-050510.md) | [96.4](/filings/0001104659-26-050510.md) | [99.3](/filings/0001104659-26-050510.md) | [51.3 d](/filings/0001104659-26-090515.md) | [68.8](/filings/0001104659-26-117480.md) | [99.5](/filings/0001104659-26-050510.md) | [88.5](/filings/0001104659-26-050510.md) | [81.4 d](/filings/0001104659-26-090515.md) | [64.9](/filings/0001104659-26-117480.md) |
| Diluted EPS | $ per share | [1.54](/filings/0001558370-25-000455.md) | [1.60](/filings/0001558370-25-005882.md) | not reported | [0.94](/filings/0001104659-25-103288.md) | [2.03](/filings/0001104659-26-007063.md) | [2.02](/filings/0001104659-26-050510.md) | not reported | [1.40](/filings/0001104659-26-117480.md) | [2.12](/filings/0001104659-26-007063.md) | [1.93](/filings/0001104659-26-050510.md) | not reported | [1.45](/filings/0001104659-26-117480.md) |
| Basic EPS | $ per share | [1.57](/filings/0001558370-25-000455.md) | [1.63](/filings/0001558370-25-005882.md) | not reported | [0.95](/filings/0001104659-25-103288.md) | [2.24](/filings/0001104659-26-007063.md) | [2.31](/filings/0001104659-26-050510.md) | not reported | [1.59](/filings/0001104659-26-117480.md) | [2.31](/filings/0001104659-26-007063.md) | [2.09](/filings/0001104659-26-050510.md) | not reported | [1.57](/filings/0001104659-26-117480.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [354](/filings/0001558370-25-000455.md) | [377](/filings/0001558370-25-005882.md) | [501](/filings/0001558370-25-010334.md) | [318](/filings/0001558370-24-013462.md) | [515](/filings/0001104659-26-007063.md) | [529](/filings/0001104659-26-050510.md) | [782](/filings/0001104659-26-090515.md) | [518](/filings/0001104659-25-103288.md) | [497](/filings/0001104659-26-007063.md) | [614](/filings/0001104659-26-050510.md) | [755](/filings/0001104659-26-117480.md) | [548](/filings/0001104659-26-117480.md) |
| Current assets | $m | [1,089](/filings/0001558370-24-000439.md) | [1,209](/filings/0001558370-24-005496.md) | [1,245](/filings/0001558370-25-010334.md) | [1,291](/filings/0001558370-24-013462.md) | [1,388](/filings/0001558370-25-000455.md) | [1,513](/filings/0001558370-25-005882.md) | [1,633](/filings/0001104659-26-090515.md) | [1,650](/filings/0001104659-25-103288.md) | [1,600](/filings/0001104659-26-007063.md) | [1,759](/filings/0001104659-26-050510.md) | [1,716](/filings/0001104659-26-117480.md) | [1,754](/filings/0001104659-26-117480.md) |
| Total assets | $m | [1,782](/filings/0001558370-24-000439.md) | [1,892](/filings/0001558370-24-005496.md) | [1,920](/filings/0001558370-25-010334.md) | [1,972](/filings/0001558370-24-013462.md) | [2,071](/filings/0001558370-25-000455.md) | [2,208](/filings/0001558370-25-005882.md) | [2,294](/filings/0001104659-26-090515.md) | [2,333](/filings/0001104659-25-103288.md) | [2,307](/filings/0001104659-26-007063.md) | [2,447](/filings/0001104659-26-050510.md) | [2,436](/filings/0001104659-26-117480.md) | [2,531](/filings/0001104659-26-117480.md) |
| Current liabilities | $m | [241](/filings/0001558370-24-000439.md) | [282](/filings/0001558370-24-005496.md) | [244](/filings/0001558370-25-010334.md) | [231](/filings/0001558370-24-013462.md) | [231](/filings/0001558370-25-000455.md) | [270](/filings/0001558370-25-005882.md) | [303](/filings/0001104659-26-090515.md) | [244](/filings/0001104659-25-103288.md) | [220](/filings/0001104659-26-007063.md) | [283](/filings/0001104659-26-050510.md) | [289](/filings/0001104659-26-117480.md) | [686](/filings/0001104659-26-117480.md) |
| Total liabilities | $m | [750](/filings/0001558370-24-000439.md) | [789](/filings/0001558370-24-005496.md) | [744](/filings/0001558370-25-010334.md) | [758](/filings/0001558370-24-013462.md) | [753](/filings/0001558370-25-000455.md) | [791](/filings/0001558370-25-005882.md) | [814](/filings/0001104659-26-090515.md) | [806](/filings/0001104659-25-103288.md) | [759](/filings/0001104659-26-007063.md) | [805](/filings/0001104659-26-050510.md) | [803](/filings/0001104659-26-117480.md) | [859](/filings/0001104659-26-117480.md) |
| Long-term debt | $m | [414](/filings/0001558370-24-000439.md) | [414](/filings/0001558370-24-005496.md) | [415](/filings/0001558370-25-010334.md) | [415](/filings/0001558370-24-013462.md) | [416](/filings/0001558370-25-000455.md) | [416](/filings/0001558370-25-005882.md) | [416](/filings/0001104659-26-090515.md) | [417](/filings/0001104659-25-103288.md) | [417](/filings/0001104659-26-007063.md) | [418](/filings/0001104659-26-050510.md) | [418](/filings/0001104659-26-117480.md) | [418](/filings/0001104659-26-117480.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [418](/filings/0001104659-26-117480.md) |
| Shareholders' equity | $m | [1,033](/filings/0001558370-25-005882.md) | [1,103](/filings/0001558370-25-005882.md) | [1,176](/filings/0001104659-26-090515.md) | [1,214](/filings/0001104659-26-050510.md) | [1,318](/filings/0001104659-26-050510.md) | [1,417](/filings/0001104659-26-050510.md) | [1,480](/filings/0001104659-26-117480.md) | [1,527](/filings/0001104659-26-117480.md) | [1,548](/filings/0001104659-26-050510.md) | [1,642](/filings/0001104659-26-050510.md) | [1,632](/filings/0001104659-26-117480.md) | [1,672](/filings/0001104659-26-117480.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [173 d](/filings/0001558370-25-000455.md) | [68.6 d](/filings/0001558370-25-005882.md) | [172 d](/filings/0001104659-26-090515.md) | [(142)](/filings/0001104659-25-103288.md) | [223 d](/filings/0001104659-26-007063.md) | [53.1 d](/filings/0001104659-26-050510.md) | [298 d](/filings/0001104659-26-090515.md) | [(196)](/filings/0001104659-26-117480.md) | [91.8 d](/filings/0001104659-26-007063.md) | [221 d](/filings/0001104659-26-050510.md) | [317 d](/filings/0001104659-26-090515.md) | [(125)](/filings/0001104659-26-117480.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-25-000455.md) | [(0.2) d](/filings/0001558370-25-005882.md) | [0.8 d](/filings/0001104659-26-090515.md) | [0.7](/filings/0001104659-25-103288.md) | [0.5 d](/filings/0001104659-26-007063.md) | [0.2 d](/filings/0001104659-26-050510.md) | [0.4 d](/filings/0001104659-26-090515.md) | [0.3](/filings/0001104659-26-117480.md) | [(0.3) d](/filings/0001104659-26-007063.md) | [0.5 d](/filings/0001104659-26-050510.md) | [0.0 d](/filings/0001104659-26-090515.md) | [0.0](/filings/0001104659-26-117480.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001104659-26-050510.md) | [100 d](/filings/0001104659-26-090515.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [42.5](/filings/0001558370-24-000439.md) | [42.7](/filings/0001558370-24-005496.md) | [43.0](/filings/0001558370-24-013462.md) | [43.5](/filings/0001558370-25-000455.md) | [43.7](/filings/0001558370-25-005882.md) | [43.7](/filings/0001104659-25-103288.md) | [47.5](/filings/0001104659-26-007063.md) | [49.2](/filings/0001104659-26-050510.md) | [49.2](/filings/0001104659-26-117480.md) | [46.9](/filings/0001104659-26-007063.md) | [45.8](/filings/0001104659-26-050510.md) | [44.8](/filings/0001104659-26-117480.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,048,853 at 2026-10-16, from the cover of the [10-Q filed 2026-10-21](/filings/0001104659-26-117480.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.